We welcome Pol Martín Chulio to the team! He will be pursuing an industrial PhD in collaboration with the thriving biotech company ONA Therapeutics, co-supervised with Dr. Salvador Guardiola. He will be working on developing chemogenetic activation strategies for full-length antibodies.
